Actively Recruiting

Age: 18Years - 75Years
All Genders
NCT07122700

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Led by Foundation for the National Institutes of Health · Updated on 2025-08-14

400

Participants Needed

4

Research Sites

63 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.

CONDITIONS

Official Title

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed and dated informed consent form provided
  • Willingness to comply with all study procedures and available for study duration
  • Male or female aged over 18 and under 75 years
  • Exhibit metabolic dysfunction defined by either physician-diagnosed type 2 diabetes mellitus for at least 90 days with HbA1c > 6.5 and stable antidiabetic therapy, or at least one metabolic syndrome criterion: BMI > 25 kg/m2, waist circumference >102 cm for men or >88.9 cm for women, fasting triglycerides >150 mg/dL or treatment for triglycerides, HDL cholesterol <40 mg/dL for men or <50 mg/dL for women or cholesterol-lowering treatment, fasting glucose >100 mg/dL, or blood pressure systolic >130 mmHg or diastolic >85 mmHg or treatment for hypertension
  • FIB-4 score >1.3 if under 65 years old or >2.0 if over 65 years old
  • Agreement to follow lifestyle considerations throughout the study
Not Eligible

You will not qualify if you...

  • History or evidence of other chronic liver diseases besides MASLD/MASH, including viral hepatitis B or C, autoimmune liver diseases, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, hemochromatosis, drug-induced liver disease, bile duct obstruction, liver cancer, prior hepatocellular carcinoma or treatment, liver transplant history, or liver resection
  • Current or past decompensated liver disease with symptoms requiring therapy such as ascites, encephalopathy, or variceal bleeding
  • Alanine aminotransferase (ALT) level greater than five times the upper limit of normal
  • Significant alcohol use exceeding defined moderate levels in the past two years or Alcohol Use Disorders Identification Test (AUDIT) score of 7 or higher or PEth test ≥ 20 ng/ml
  • Contraindications to liver biopsy such as significant uncorrected bleeding risk or anticoagulation therapy
  • Uncontrolled blood pressure above 180/120 mmHg at screening
  • Any systemic disease preventing participation as judged by the investigator
  • Unable or unwilling to give informed consent or undergo liver biopsy
  • Inability or unwillingness to comply with study procedures including fasting
  • Unable to complete study procedures as judged by the investigator
  • Inability or unwillingness to undergo MRI due to implants or waist size over 70 cm without wide-bore MRI
  • Pregnancy or planned pregnancy within 4 months of screening
  • Participation in another clinical trial within 30 days or investigational drug use within 90 days prior to consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Clinical Pharmacology of Miami

Miami, Florida, United States, 33172

Actively Recruiting

2

Ohio Clinical Trials

Columbus, Ohio, United States, 43212

Actively Recruiting

3

First Surgical Hospital

Bellaire, Texas, United States, 77401

Actively Recruiting

4

Endeavor Clinical Trials

San Antonio, Texas, United States, 78240

Actively Recruiting

Loading map...

Research Team

G

Geraldine Dacpano

CONTACT

C

Clay Dehn

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here